CordenPharma has a new CEO, Arbour Group advances plans to expand in RTP, Ashfield brings on a former Iqvia VP, and Recursion adds to its c-suite after raising $121m this month.
Growing need for validated storage capacity sees Lyophilization Services of New England complete an expansion its cGMP storage capabilities at its New Hampshire site.
Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating an end-to-end ordering and manufacturing process in support of cell and gene therapy development.
Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.
Cambrex to scale up its solid form screening and crystallization process development facility in Edinburgh to answer market demand for larger scale crystallization.
To further support Asia-Pacific oncology trials, NeoGenomics opens new Singapore-based pharma services laboratory in the same building as PPD Laboratories’ central lab.
Sanofi to manufacture and commercialize Opiant’s investigational treatment for acute cannabinoid overdose, which could become the first treatment for the condition.
The acquisition of two migraine therapies from Dr Reddy’s has been completed by Upsher-Smith, adding different drug delivery treatment options to its migraine product portfolio.
Years in the making, ACRES launches a global accreditation program, which will ‘dramatically’ benefit all research stakeholders, including sponsors, CROs, regulators, monitors, as well as patients, says CEO.
July has seen a number of actions taken by regulators to manage the supply of medicine, including a crackdown on CBD manufacturers and repackers of opioid medication.
Phesi launches an AI-powered SaaS solution to mitigate potential costly delays through a search and select investigator function to determine trial sites for clinical studies.
Immodulon to utilize biomarkers identified by Biodesix’ machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment.
Litmus Health today released a new version of its end-to-end real-world data platform for clinical research – as the industry increasingly adopts wearable technology to monitor patients in their homes, says CMO.
Merck to invest in its North Carolina facilities as it expands production capacity to meet demand for its HPV vaccine Gardasil, and grow its packaging operations
Veristat launches clinical trial, biostatistics, and programming operations in Taipei, Taiwan in response to increasing client demand for regulatory submission support for both local and North American-based sponsors.
O2h Ventures and AI Fund invest in Small Pharma, as it works to complete studies for its lead program, a metabolite of ketamine as an oral anti-depressant.
TransCelerate BioPharma – and its subsidiary BioCelerate – launch new initiatives aimed at enhancing the research and development ecosystem, progressing its mission of getting innovative therapies to patients faster, says EVP.
Freenome is working with a CRO as part of a clinical trial evaluating the company’s multi-omics blood testing platform – which the CEO says helps de-risk drug development by characterizing likely responders to therapy, among other use cases.
Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.
Civica and Hikma agree a manufacture and supply partnership to increase access to 14 essential sterile injectable medicines for the US hospital network.
A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.
Theralase taps an undisclosed trial management organization for the site selection of its multi-country bladder cancer study which aims to enroll 100 patients across 20 sites.
Insilico Medicine develops a semi-automated contracting system to ease the collaboration process between AI companies and industry partners in the discovery space.
Dassault Systèmes’ Living Heart Project is moving forward with an in silico clinical trial underway and plans to evaluate the use of virtual patients – as the French software company hopes to reduce costs, timelines, and improve quality across the industry,...
MIT has developed an ‘invisible’ device that provides several benefits over traditional patient data collection methods, including improved biomarker development and the ability to detect changes in behavior – by monitoring patients wirelessly, and through...
Parexel’s consulting subsidiary Health Advances opens in Hong Kong to provide business strategy as well as scientific and clinical expertise to customers in the region.
Syapse today announces a strategic collaboration with Pfizer through which it will generate insights from de-identified real-world data and advance oncology outcomes research.
Meridian Clinical Research acquires Regional Clinical Research in a deal that will see its North American footprint expand to more than 20 investigative clinical trial sites.
Janssen aims to expand the label of delivery in the US and EU for its product, Darzalex, to include subcutaneous delivery through the use of Halozyme’s technology.
Astellas agrees a deal for the ex-US rights of Frequency’s lead drug candidate, FX-322, after the latter company posted positive results in a Phase I/II trial.
A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.
Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
